John O Mascarenhas, MD Email John Mascarenhas
- ASSOCIATE PROFESSOR | Medicine, Hematology and Medical Oncology
- Cancer (Oncology)
- Hospital Affiliation
- The Mount Sinai Hospital
- Ruttenberg Treatment Center 212-241-6756 212-241-6756
Book an Appointment - John O Mascarenhas, MD
Dr. John Mascarenhas is an Associate Professor of Medicine at the Icahn School of Medicine at Mount Sinai (ISMMS) and a member of the Tisch Cancer Institute. Dr. Mascarenhas is the Director of the Adult Leukemia Program and Leader of Clinical Investigation within the Myeloproliferative Disorders Program at Mount Sinai, under the direction of Dr. Ronald Hoffman. As a clinical investigator in malignant hematology with a focus in translational research involving myeloproliferative neoplasms (MPNs) and evolution to acute myeloid leukemia (AML), he is focused on the evaluation of rationale based novel therapies for patients with MPNs and AML. Dr. Mascarenhas is also the Principal Investigator (PI) of the clinical trials project within the National Cancer Institute sponsored Myeloproliferative Disorder Research Consortium (MPD-RC). He has served as PI or Study Chair of multiple investigator-initiated and industry-sponsored early and late phase clinical trials evaluating innovative approaches to the treatment of MPNs and AML. Additionally, he holds multiple administrative roles at Mount Sinai including Chair of the Leukemia Disease Management Team, Co-Chair of the Hematologic Malignancy Disease Focus Group, and full member of the Tisch Cancer Institute Protocol and Review Monitoring Committee.
Acute myeloid leukemia
Chronic myelogenous leukemia
Chronic neutrophilic leukemia
Chronic myelomonocytic leukemia
- Acute Myelogenous Leukemia—Adult
- Aplastic Anemia
- Blood Transfusion
- Chronic Myelocytic Leukemia
- Myelodysplastic Syndromes
- Primary Polycythemia
MD, New York Medical College
Residency, Internal Medicine
Rhode Island Hospital
Mount Sinai Hospital
Richard E. Rosenfeld Faculty Achievement Award
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Mascarenhas during 2019 and/or 2020. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
- Celgene Corporation
Scientific Advisory Board:
- CTI Biopharma
- Incyte Corporation
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.